Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: intravenous GAD - Mertiva

Drug Profile

Research programme: intravenous GAD - Mertiva

Alternative Names: GAD 67; GAD65 intravenous - Diamyd Medical; rhGAD65 intravenous - Diamyd Medical

Latest Information Update: 30 Apr 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mertiva
  • Class
  • Mechanism of Action Enzyme modulators; GABA modulators; Glutamate decarboxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Epilepsy; Movement disorders; Stiff-person syndrome

Most Recent Events

  • 30 Apr 2013 No development reported - Preclinical for Epilepsy in USA (IV)
  • 30 Apr 2013 No development reported - Preclinical for Movement disorders in USA (IV)
  • 30 Apr 2013 No development reported - Preclinical for Stiff-person syndrome in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top